Accessibility Menu
Reviva Pharmaceuticals logo

Reviva Pharmaceuticals(OTC) RVPH

Current Price$0.50
Market Cap$6.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-99%
1 Year-94%
1 Month-32%
Reviva Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.472026-07-23
Reviva Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-14.7%USD 0.552026-07-16
1 month-32.37%USD 0.702026-06-23
3 month-47.8%USD 0.902026-04-24
Year to date-91.58%USD 5.582025-12-31
1 year-94.42%USD 8.422025-07-23
3 year-99.5%USD 93.802023-07-24
5 year-99.39%USD 76.602021-07-23
Since inception-99.76%USD 194.202018-10-18

Reviva Pharmaceuticals Financials at a Glance

Market Cap

$6.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$16.63M

EPS (TTM)

-$4.56

P/E Ratio

-0.10

Dividend

$0.00

Beta (Volatility)

0.77 (Low)

Price

$0.50

Volume

14,408

Open

$0.50

Previous Close

$0.47

Daily Range

$0.47 - $0.55

52-Week Range

$0.26 - $17.20

Estimated Earnings Date

Aug 13, 2026

RVPH News

Foolcom-Featured.png

Reviva Narrows Loss 23% in Fiscal Q2

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Reviva Pharmaceuticals

Reviva develops medicines for mental health and rare lung diseases. Its main drug aims to help people with schizophrenia. The company also researches treatments for depression and obesity.

What’s in the Medicine Cabinet?

  • Brilaroxazine (RP5063): Lead drug in late-stage trials for schizophrenia; also studied for bipolar disorder, depression, attention disorders, dementia, Parkinson’s psychosis, and rare lung diseases. Represents 0% of revenue as of June 2025.
  • RP1208: Early-stage drug candidate for depression and obesity; not yet in human trials. Represents 0% of revenue as of June 2025.
  • Intellectual Property: Holds 70 patents and 12 pending applications in the US and over 20 other countries.

Growth Moves: The Expansion Playbook

  • Completed Phase III trial for brilaroxazine in schizophrenia in 2025.
  • Finished a one-year safety study for brilaroxazine in 2025.
  • Raised $10 million in a public offering in June 2025.
  • Launched an at-the-market (ATM) program in May 2025, authorizing up to $50 million in new funding.

Why Reviva Stands Out in the Crowd

Reviva uses its own technology to discover new drugs for hard-to-treat diseases. The company’s main drug targets several mental and lung conditions, with broad patent protection. Orphan Drug status for rare lung diseases may offer regulatory benefits.

Five Things You Need to Know

  • No revenue reported for Q2 2025, Q2 2024, or Q2 2023.
  • Net loss was $6 million in Q2 2025, down 49.7% from Q2 2023.
  • Cash and cash equivalents were $10.4 million as of June 30, 2025.
  • Company expects to need more funding by early 2026 to continue operations.

Bottom Line

Reviva focuses on new treatments for mental and rare lung diseases. The company remains in the research stage and relies on outside funding to continue its work.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

14

CEO

Laxminarayan Bhat, PhD

Website

www.revivapharma.com

Headquarters

Cupertino, CA 95014, US

RVPH Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-220.39%

Return on Capital

-223.09%

Return on Assets

-70.58%

Earnings Yield

-10.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

12.81M

Volume

14.41K

Avg. Volume

381.47K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$16.93M

EBITDA

-$16.61M

Operating Cash Flow

-$20.20M

Capital Expenditure

$0.00

Free Cash Flow

-$20.20M

Cash & ST Invst.

$22.19M

Total Debt

$231.27K

Reviva Pharmaceuticals Performance Analysis

Reviva Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Reviva Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Reviva Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -28.96151.3%
20232023-12-31USD -32.9913.9%
20242024-12-31USD -18.05-45.3%
20252025-12-31USD -5.48-69.7%
Reviva Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-307.7%
Q32025-09-3054.0%
Q42025-12-31-371.9%
Q12026-03-3191.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$6.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$430.06K

N/A

Employees

14

N/A

Net Income

-$3.20M

+50.3%

EBITDA

-$3.19M

+50.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$22.19M

+319.5%

Total Debt

$231.27K

+3.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$231.27K

+3.1%

Return on Assets

-70.58%

N/A

Return on Invested Capital

-97.09%

N/A

Free Cash Flow

-$3.80M

+53.6%

Operating Cash Flow

-$3.80M

+53.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BCABBioAtla, Inc.
$3.37-2.60%
CELUCelularity Inc.
$0.76+0.29%
EVAXEvaxion Biotech A/S
$3.00-1.64%
TVRDTvardi Therapeutics, Inc.
$2.54-0.98%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.22-0.07%
AALAmerican Airlines Group
$14.45+0.07%
CLFCleveland-Cliffs
$11.91+0.09%
MARAMara Holdings
$12.57-0.02%

Questions About RVPH

What is the current price of Reviva Pharmaceuticals?

Reviva Pharmaceuticals is trading at $0.50 per share.

What is the 52-week range for Reviva Pharmaceuticals?

Over the past 52 weeks, Reviva Pharmaceuticals has traded between $0.26 and $17.20.

How much debt does Reviva Pharmaceuticals have?

As of the most recent reporting period, Reviva Pharmaceuticals reported total debt of $231.27K.

How much cash does Reviva Pharmaceuticals have on hand?

Reviva Pharmaceuticals reported $22.19M in cash and cash equivalents in its most recent financial results.

What is Reviva Pharmaceuticals’s dividend yield?

Reviva Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services